Illumina has formed a collaborative partnership with leading pharmaceutical companies AstraZeneca, Janssen Biotech and Sanofi.
The collaborative partnership aims to develop a paradigm-shifting universal next-generation sequencing (NGS)-based system for oncology research and drug development.
Once Illumina achieves regulatory approval, the company will commercialize the system.
Thus far, cancer researchers have identified 125 cancer driver genes—71 tumor suppressors and 54 oncogenes—that lead to tumor growth via 12 cellular signaling pathways.
The rise of targeted drugs requires more accurate, and specific, diagnostic testing—which is what Illumina wants to achieve with its new universal NGS-based test system.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity